Welcome to our dedicated page for Genprex news (Ticker: GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex stock.
Genprex, Inc. develops clinical-stage gene therapies for cancer and diabetes, with recurring updates centered on Reqorsa® Gene Therapy (quaratusugene ozeplasmid) and its diabetes gene therapy candidate Pdx1/MafA, also referred to as GPX-002. Reqorsa uses a non-viral, lipid-based nanoparticle delivery approach for a TUSC2 gene-expressing plasmid and is being developed with approved cancer drugs for non-small cell lung cancer and small cell lung cancer.
Company news commonly covers patent grants and licensed intellectual property for Reqorsa combinations with PD-1 and PD-L1 antibodies, biomarker research involving TROP2 and PTEN, preclinical and clinical data presentations, sponsored research with UT MD Anderson, oncology trial references such as Acclaim-1 and Acclaim-3, diabetes preclinical research, industry conference participation and Nasdaq compliance updates.
Genprex (NASDAQ:GNPX) announced its upcoming presentation at the LD 500 Virtual Investor Conference on September 1, 2020, at 1:20 p.m. ET. CEO Rodney Varner will discuss the company's product pipeline, highlighting GPX-001, which has received Fast Track Designation from the FDA for late-stage lung cancer treatment. The presentation will be available via live webcast on the conference and company websites. Genprex focuses on gene therapy advancements for cancer and diabetes, aiming to provide new treatment options.